デフォルト表紙
市場調査レポート
商品コード
1411530

CAR T細胞療法市場:適応症別、最終用途別-2024-2030年の世界予測

CAR T-cell Therapy Market by Indication (Hematologic Malignancies, Solid Tumors), End-Use (Cancer Treatment Centers, Hospitals) - Global Forecast 2024-2030

出版日: | 発行: 360iResearch | ページ情報: 英文 195 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.16円
CAR T細胞療法市場:適応症別、最終用途別-2024-2030年の世界予測
出版日: 2024年01月16日
発行: 360iResearch
ページ情報: 英文 195 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

CAR T細胞療法市場規模は2023年に50億8,000万米ドルと推計され、2024年には53億5,000万米ドルに達し、CAGR 5.00%で2030年には71億5,000万米ドルに達すると予測されます。

CAR T細胞療法の世界市場

主な市場の統計
基準年[2023] 50億8,000万米ドル
予測年[2024] 53億5,000万米ドル
予測年 [2030] 71億5,000万米ドル
CAGR(%) 5%
CAR T細胞療法 Market-IMG1

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスはCAR T細胞療法市場を評価する上で極めて重要です。事業戦略と製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます:フォアフロント(F)、パスファインダー(P)、ニッチ(N)、バイタル(V)です。

市場シェア分析

市場シェア分析は、CAR T細胞療法市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています:

1-市場の浸透度:主要企業が提供する市場に関する包括的な情報を提示しています。

2-市場の開拓度:有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3-市場の多様化:新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4-競合の評価と情報:市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5-製品開発およびイノベーション:将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています:

1-CAR T細胞療法市場の市場規模および予測は?

2-CAR T細胞療法市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か?

3-CAR T細胞療法市場における技術動向と規制の枠組みは?

4-CAR T細胞療法市場における主要ベンダーの市場シェアは?

5-CAR T細胞療法市場への参入に適した形態や戦略的手段は?

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 多発性骨髄腫がん、リンパ腫、白血病の罹患率の上昇
      • 政府の認識に基づくCAR T細胞療法に対する適切な払い戻しの利用可能性
      • 遺伝子治療と細胞治療の採用の増加
    • 抑制要因
      • CAR T細胞免疫療法の有効性の限界
    • 機会
      • 先住民族のCAR-T療法に対する飛躍的な研究開発資金とパートナーシップ
      • CAR T細胞免疫療法の導入に対する政府の支援と取り組み
    • 課題
      • 安全性と副作用の可能性に関する懸念
  • 市場セグメンテーション分析
  • 市場動向分析
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み

第6章 CAR T細胞療法市場適応症別

  • 血液悪性腫瘍
    • 白血病
    • リンパ腫
    • 骨髄腫
  • 固形腫瘍
    • 脳と中枢神経系
    • 肝臓がん
    • 黒色腫

第7章 CAR T細胞療法市場:最終用途別

  • がん治療センター
  • 病院

第8章 南北アメリカのCAR T細胞療法市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第9章 アジア太平洋地域のCAR T細胞療法市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第10章 欧州・中東・アフリカのCAR T細胞療法市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第11章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析:主要企業別
  • 競合シナリオ主要企業別の分析

第12章 競争力のあるポートフォリオ

  • 主要な企業プロファイル
    • AbClon Inc.
    • Abintus Bio, Inc.
    • AffyImmune Therapeutics Inc.
    • Aleta Biotherapeutics
    • Amgen Inc.
    • Anixa Biosciences, Inc.
    • Aurora BioPharma, Inc.
    • Autolus Therapeutics PLC
    • Bellicum Pharmaceuticals, Inc.
    • BioNTech SE
    • Bristol-Myers Squibb Company
    • CARsgen Therapeutics Holdings Limited by Huadong Medicine Co., Ltd.
    • Cellectis SA
    • Celyad Oncology SA
    • Fate Therapeutics, Inc.
    • Gilead Sciences, Inc.
    • Intellia Therapeutics, Inc.
    • Janssen Global Services, LLC by Johnson & Johnson Services, Inc.
    • Legend Biotech Corporation by Genscript Biotech Corporation
    • Les Laboratories Servier
    • Mustang Bio by Fortress Biotech, Inc.
    • Noile-immune Biotech, Inc.
    • Novartis AG
    • Pfizer Inc.
    • Sorrento Therapeutics, Inc.
  • 主要な製品ポートフォリオ

第13章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. CAR T-CELL THERAPY MARKET RESEARCH PROCESS
  • FIGURE 2. CAR T-CELL THERAPY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. CAR T-CELL THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. CAR T-CELL THERAPY MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. CAR T-CELL THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. CAR T-CELL THERAPY MARKET DYNAMICS
  • FIGURE 7. CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 8. CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 10. CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 12. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES CAR T-CELL THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 14. UNITED STATES CAR T-CELL THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. CAR T-CELL THERAPY MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 20. CAR T-CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. CAR T-CELL THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. CAR T-CELL THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 6. CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 8. CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. CAR T-CELL THERAPY MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. CAR T-CELL THERAPY MARKET SIZE, BY MYELOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 13. CAR T-CELL THERAPY MARKET SIZE, BY BRAIN & CENTRAL NERVOUS SYSTEM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. CAR T-CELL THERAPY MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. CAR T-CELL THERAPY MARKET SIZE, BY MELANOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 17. CAR T-CELL THERAPY MARKET SIZE, BY CANCER TREATMENT CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. CAR T-CELL THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES CAR T-CELL THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 45. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 50. AUSTRALIA CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 51. AUSTRALIA CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 52. AUSTRALIA CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 54. CHINA CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 55. CHINA CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 56. CHINA CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 58. INDIA CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 59. INDIA CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 60. INDIA CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 62. INDONESIA CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 63. INDONESIA CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 64. INDONESIA CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 66. JAPAN CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 67. JAPAN CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 68. JAPAN CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 70. MALAYSIA CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 71. MALAYSIA CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 72. MALAYSIA CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 74. PHILIPPINES CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 75. PHILIPPINES CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 76. PHILIPPINES CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 78. SINGAPORE CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 79. SINGAPORE CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 80. SINGAPORE CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 82. SOUTH KOREA CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 83. SOUTH KOREA CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 84. SOUTH KOREA CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 86. TAIWAN CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 87. TAIWAN CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 88. TAIWAN CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 90. THAILAND CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 91. THAILAND CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 92. THAILAND CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 94. VIETNAM CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 95. VIETNAM CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 96. VIETNAM CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 103. DENMARK CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 104. DENMARK CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 105. DENMARK CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 107. EGYPT CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 108. EGYPT CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 109. EGYPT CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 111. FINLAND CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 112. FINLAND CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 113. FINLAND CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 115. FRANCE CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 116. FRANCE CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 117. FRANCE CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 119. GERMANY CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 120. GERMANY CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 121. GERMANY CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 123. ISRAEL CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 124. ISRAEL CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 125. ISRAEL CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 127. ITALY CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 128. ITALY CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 129. ITALY CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 131. NETHERLANDS CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 132. NETHERLANDS CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 133. NETHERLANDS CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 135. NIGERIA CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 136. NIGERIA CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 137. NIGERIA CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 139. NORWAY CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 140. NORWAY CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 141. NORWAY CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 143. POLAND CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 144. POLAND CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 145. POLAND CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 147. QATAR CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 148. QATAR CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 149. QATAR CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 151. RUSSIA CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 152. RUSSIA CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 153. RUSSIA CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 155. SAUDI ARABIA CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 156. SAUDI ARABIA CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 157. SAUDI ARABIA CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 159. SOUTH AFRICA CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 160. SOUTH AFRICA CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 161. SOUTH AFRICA CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 163. SPAIN CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 164. SPAIN CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 165. SPAIN CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 167. SWEDEN CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 168. SWEDEN CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 169. SWEDEN CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 171. SWITZERLAND CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 172. SWITZERLAND CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 173. SWITZERLAND CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 175. TURKEY CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 176. TURKEY CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 177. TURKEY CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 179. UNITED ARAB EMIRATES CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 180. UNITED ARAB EMIRATES CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 181. UNITED ARAB EMIRATES CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED KINGDOM CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED KINGDOM CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED KINGDOM CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 187. CAR T-CELL THERAPY MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 188. CAR T-CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 189. CAR T-CELL THERAPY MARKET LICENSE & PRICING
目次
Product Code: MRR-1E2F1ED7E6BC

[195 Pages Report] The CAR T-cell Therapy Market size was estimated at USD 5.08 billion in 2023 and expected to reach USD 5.35 billion in 2024, at a CAGR 5.00% to reach USD 7.15 billion by 2030.

Global CAR T-cell Therapy Market

KEY MARKET STATISTICS
Base Year [2023] USD 5.08 billion
Estimated Year [2024] USD 5.35 billion
Forecast Year [2030] USD 7.15 billion
CAGR (%) 5%
CAR T-cell Therapy Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the CAR T-cell Therapy Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the CAR T-cell Therapy Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the CAR T-cell Therapy Market, highlighting leading vendors and their innovative profiles. These include AbClon Inc., Abintus Bio, Inc., AffyImmune Therapeutics Inc., Aleta Biotherapeutics, Amgen Inc., Anixa Biosciences, Inc., Aurora BioPharma, Inc., Autolus Therapeutics PLC, Bellicum Pharmaceuticals, Inc., BioNTech SE, Bristol-Myers Squibb Company, CARsgen Therapeutics Holdings Limited by Huadong Medicine Co., Ltd., Cellectis SA, Celyad Oncology SA, Fate Therapeutics, Inc., Gilead Sciences, Inc., Intellia Therapeutics, Inc., Janssen Global Services, LLC by Johnson & Johnson Services, Inc., Legend Biotech Corporation by Genscript Biotech Corporation, Les Laboratories Servier, Mustang Bio by Fortress Biotech, Inc., Noile-immune Biotech, Inc., Novartis AG, Pfizer Inc., and Sorrento Therapeutics, Inc..

Market Segmentation & Coverage

This research report categorizes the CAR T-cell Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Indication
    • Hematologic Malignancies
      • Leukemia
      • Lymphoma
      • Myeloma
    • Solid Tumors
      • Brain & Central Nervous System
      • Liver Cancer
      • Melanoma
  • End-Use
    • Cancer Treatment Centers
    • Hospitals
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the CAR T-cell Therapy Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the CAR T-cell Therapy Market?

3. What are the technology trends and regulatory frameworks in the CAR T-cell Therapy Market?

4. What is the market share of the leading vendors in the CAR T-cell Therapy Market?

5. Which modes and strategic moves are suitable for entering the CAR T-cell Therapy Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. CAR T-cell Therapy Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rise in the prevalence of multiple myeloma cancer, lymphoma and leukemia
      • 5.1.1.2. Availability of adequate reimbursements for CAR T-cell therapy with government awareness
      • 5.1.1.3. Increasing adoption of gene and cell therapy
    • 5.1.2. Restraints
      • 5.1.2.1. Limitations of the efficacy of CAR T-cell immunotherapy
    • 5.1.3. Opportunities
      • 5.1.3.1. Exponential R&D funding and partnership for indigenous CAR-T therapy
      • 5.1.3.2. Government support and initiative for the adoption of CAR T-cell immunotherapy
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns associated with safety and possible side effects
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. CAR T-cell Therapy Market, by Indication

  • 6.1. Introduction
  • 6.2. Hematologic Malignancies
    • 6.3.1. Leukemia
    • 6.3.2. Lymphoma
    • 6.3.3. Myeloma
  • 6.3. Solid Tumors
    • 6.4.1. Brain & Central Nervous System
    • 6.4.2. Liver Cancer
    • 6.4.3. Melanoma

7. CAR T-cell Therapy Market, by End-Use

  • 7.1. Introduction
  • 7.2. Cancer Treatment Centers
  • 7.3. Hospitals

8. Americas CAR T-cell Therapy Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific CAR T-cell Therapy Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa CAR T-cell Therapy Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. FPNV Positioning Matrix
  • 11.2. Market Share Analysis, By Key Player
  • 11.3. Competitive Scenario Analysis, By Key Player

12. Competitive Portfolio

  • 12.1. Key Company Profiles
    • 12.1.1. AbClon Inc.
    • 12.1.2. Abintus Bio, Inc.
    • 12.1.3. AffyImmune Therapeutics Inc.
    • 12.1.4. Aleta Biotherapeutics
    • 12.1.5. Amgen Inc.
    • 12.1.6. Anixa Biosciences, Inc.
    • 12.1.7. Aurora BioPharma, Inc.
    • 12.1.8. Autolus Therapeutics PLC
    • 12.1.9. Bellicum Pharmaceuticals, Inc.
    • 12.1.10. BioNTech SE
    • 12.1.11. Bristol-Myers Squibb Company
    • 12.1.12. CARsgen Therapeutics Holdings Limited by Huadong Medicine Co., Ltd.
    • 12.1.13. Cellectis SA
    • 12.1.14. Celyad Oncology SA
    • 12.1.15. Fate Therapeutics, Inc.
    • 12.1.16. Gilead Sciences, Inc.
    • 12.1.17. Intellia Therapeutics, Inc.
    • 12.1.18. Janssen Global Services, LLC by Johnson & Johnson Services, Inc.
    • 12.1.19. Legend Biotech Corporation by Genscript Biotech Corporation
    • 12.1.20. Les Laboratories Servier
    • 12.1.21. Mustang Bio by Fortress Biotech, Inc.
    • 12.1.22. Noile-immune Biotech, Inc.
    • 12.1.23. Novartis AG
    • 12.1.24. Pfizer Inc.
    • 12.1.25. Sorrento Therapeutics, Inc.
  • 12.2. Key Product Portfolio

13. Appendix

  • 13.1. Discussion Guide
  • 13.2. License & Pricing